吡美诺在青年和老年受试者中的药代动力学。

Pharmacokinetics of pirmenol in young and elderly subjects.

作者信息

Ferry D G, Campbell A J, Bland R, Beasley M, Gazeley L, Edwards I R

机构信息

National Toxicology Group, University of Otago Medical School, Dunedin, New Zealand.

出版信息

Eur J Clin Pharmacol. 1992;43(4):437-9. doi: 10.1007/BF02220624.

DOI:10.1007/BF02220624

PMID:1451728

Abstract

The steady state pharmacokinetics of pirmenol was compared in twelve healthy young (aged 18 to 45 y) and 11 elderly subjects (over 65 y) subjects given pirmenol HCl 100 mg every 12 h for a total of 14 doses. In addition, the single-dose pharmacokinetics of pirmenol was determined following a 100 mg oral dose in the young subject group for comparison with the results of repeated administration. In the young subjects, the mean single-dose and steady-state CLR of pirmenol were similar; however, Ae was 29% higher and CL/f was 22% lower at steady state than after the single dose. Steady-state (fourteenth dose) Cmin, Cmax, tmax, lambda z, Ae, CL/f, CLR and V values were similar in the young and elderly subjects. Based on pharmacokinetic considerations, the dosage of pirmenol is unlikely to differ in young and elderly subjects.

摘要

在12名健康年轻受试者（年龄18至45岁）和11名老年受试者（65岁以上）中比较了吡美诺的稳态药代动力学，这些受试者每12小时服用100 mg盐酸吡美诺，共服用14剂。此外，在年轻受试者组中口服100 mg剂量后测定了吡美诺的单剂量药代动力学，以便与重复给药的结果进行比较。在年轻受试者中，吡美诺的平均单剂量和稳态清除率相似；然而，稳态时的Ae高29%，CL/f比单剂量后低22%。年轻和老年受试者的稳态（第14剂）Cmin、Cmax、tmax、λz、Ae、CL/f、CLR和V值相似。基于药代动力学考虑，吡美诺在年轻和老年受试者中的剂量不太可能不同。